Asset
DIPRAGLURANT
ADDEX THERAPEUTICS LTD AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01336088 | phase2 | completed | 2011-04-01 | 2012-02-01 | Addex Pharma S.A. | ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease |
| NCT04857359 | phase2_3 | terminated | 2021-08-06 | 2022-06-17 | Addex Pharma S.A. | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
| NCT05027997 | phase2 | completed | 2021-10-06 | 2022-10-27 | Addex Pharma S.A. | Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm |
| NCT05116813 | phase2_3 | terminated | 2021-10-25 | 2022-06-17 | Addex Pharma S.A. | Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
FDA applications (0)
This company has no applications containing this asset.